MSB 2.91% $1.06 mesoblast limited

11 Billion for this pipeline would make MSB's estimated...

  1. 496 Posts.
    lightbulb Created with Sketch. 251

    11 Billion for this pipeline would make MSB's estimated valuation rather large by comparison.


    Prometheus Biosciences therapeutic pipeline


    ProgramIndicationPreclinicalPhase 1Phase 2Phase 3
    PRA023
    TL1A mAb
    Ulcerative Colitis




    Crohn's Disease




    SSc-ILD




    PRA052*
    CD30 ligand mAb
    Immune-Mediated Diseases




    PR1100
    Cytokine receptor mAb
    Immune-Mediated Diseases




    PR2100
    Inflammatory cytokine mAb
    Immune-Mediated Diseases




    PR300
    GPCR small molecule
    Immune-Mediated Diseases




    *Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand


    https://hotcopper.com.au/data/attachments/5311/5311670-82bba025b606eb1d7341ca39ba576ad3.jpg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.06
Change
0.030(2.91%)
Mkt cap ! $1.210B
Open High Low Value Volume
$1.05 $1.09 $1.03 $5.796M 5.430M

Buyers (Bids)

No. Vol. Price($)
2 15990 $1.06
 

Sellers (Offers)

Price($) Vol. No.
$1.08 48632 3
View Market Depth
Last trade - 16.10pm 02/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.